These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3573809)

  • 1. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation.
    Müller B; Müller-Ruchholtz W
    Leuk Res; 1987; 11(5):461-8. PubMed ID: 3573809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
    Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
    Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
    Vogel CW; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7707-11. PubMed ID: 6950410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
    Parker CJ; White VF; Falk RJ
    Complement; 1986; 3(4):223-35. PubMed ID: 3643079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cobra complement system: I. The alternative pathway of activation.
    Vogel CW; Müller-Eberhard HJ
    Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach.
    Juhl H; Sievers M; Baltzer K; Helmig F; Wolf H; Brenner W; Kalthoff H
    Cancer Res; 1995 Dec; 55(23 Suppl):5749s-5755s. PubMed ID: 7493340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation.
    Zara J; Pomato N; McCabe RP; Bredehorst R; Vogel CW
    Bioconjug Chem; 1995; 6(4):367-72. PubMed ID: 7578355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytolysis of Sendai virus-infected guinea-pig cells by homologous complement.
    Okada H; Tanaka H; Okada N
    Immunology; 1983 May; 49(1):29-35. PubMed ID: 6301976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of vertebrate complement by Helix pomatia haemolymph.
    Koch C; Nielsen HE
    Dev Comp Immunol; 1984; 8(1):15-22. PubMed ID: 6562978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
    Edens RE; Linhardt RJ; Bell CS; Weiler JM
    Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
    Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
    Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci.
    Shigeoka AO; Jensen CL; Pincus SH; Hill HR
    J Infect Dis; 1984 Jul; 150(1):63-70. PubMed ID: 6379061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the optimal reaction conditions for assay of the mouse alternative complement pathway.
    Van Dijk H; Rademaker PM; Klerx JP; Willers JM
    J Immunol Methods; 1985 Dec; 85(2):233-43. PubMed ID: 4078314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
    Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
    Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and properties of a complement inhibitor from Naja haje venom, distinct from known anticomplementary factors in cobra venom.
    von Zabern I; Przyklenk H; Damerau B; Zimmermann B
    Scand J Immunol; 1981 Aug; 14(2):109-20. PubMed ID: 6914809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A monoclonal antibody which blocks the function of factor D of human complement.
    Pascual M; Catana E; Spertini F; Macon K; Volanakis JE; Schifferli JA
    J Immunol Methods; 1990 Mar; 127(2):263-9. PubMed ID: 2313104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of the complement activating protein in the venom of the Indian cobra (Naja N. siamensis).
    Eggertsen G; Lind P; Sjöquist J
    Mol Immunol; 1981 Feb; 18(2):125-33. PubMed ID: 6790937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.